From my understanding Amgen (NASDAQ:AMGN) is manufacturing denosumab (AMG162) at the Longmont, CO facility and announced results from the first Phase III pivotal study of the monoclonal antibodies effect on bone density across the skeleton in women with non-metastatic breast cancer who were receiving adjuvant Aromatase Inhibitor therapy (AI’s lower the amount of estrogen in [...]